[go: up one dir, main page]

PE20190416A1 - Anticuerpos antifactor de la coagulacion xi - Google Patents

Anticuerpos antifactor de la coagulacion xi

Info

Publication number
PE20190416A1
PE20190416A1 PE2018003203A PE2018003203A PE20190416A1 PE 20190416 A1 PE20190416 A1 PE 20190416A1 PE 2018003203 A PE2018003203 A PE 2018003203A PE 2018003203 A PE2018003203 A PE 2018003203A PE 20190416 A1 PE20190416 A1 PE 20190416A1
Authority
PE
Peru
Prior art keywords
alphafxi
family
antibody
fxi
antibodies
Prior art date
Application number
PE2018003203A
Other languages
English (en)
Inventor
Zhu Chen
Kenneth P Ellsworth
James Milligan
Elizabeth Oldham
Dietmar Seiffert
Vaishnavi Ganti
Mohammad Tabrizifard
Bianka Prinz
Original Assignee
Merck Sharp & Dohme
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Adimab Llc filed Critical Merck Sharp & Dohme
Publication of PE20190416A1 publication Critical patent/PE20190416A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referido a anticuerpos antifactor de la coagulacion XI, en donde el anticuerpo o fragmento de union al antigeno comprende al menos las 6 regiones determinantes de la complementariedad (CDR) de un anticuerpo anti-FXI de la familia alfaFXI-18623p, la familia alfaFXI-18611p, o la familia alfaFXI-18611, en la que una o mas de las seis CDR tiene una, dos o tres sustituciones, adiciones o deleciones de aminoacidos, o combinaciones de las mismas. Ademas, se describen anticuerpo o fragmento de union al antigeno que se unen al dominio Apple 3 del factor de coagulacion FXI e inhibe la activacion del FXI y/o la activacion del factor IX mediada por el XIa.
PE2018003203A 2016-06-14 2017-06-12 Anticuerpos antifactor de la coagulacion xi PE20190416A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662349888P 2016-06-14 2016-06-14

Publications (1)

Publication Number Publication Date
PE20190416A1 true PE20190416A1 (es) 2019-03-19

Family

ID=59078269

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018003203A PE20190416A1 (es) 2016-06-14 2017-06-12 Anticuerpos antifactor de la coagulacion xi

Country Status (29)

Country Link
US (6) US10676536B2 (es)
EP (1) EP3469002A1 (es)
JP (2) JP7022081B2 (es)
KR (2) KR102379580B1 (es)
CN (2) CN109476758B (es)
AR (1) AR108717A1 (es)
AU (3) AU2017286432B2 (es)
BR (1) BR112018075858A2 (es)
CA (2) CA3025869C (es)
CL (2) CL2018003565A1 (es)
CO (1) CO2018013434A2 (es)
CR (1) CR20180583A (es)
DO (1) DOP2018000284A (es)
EA (1) EA201892716A1 (es)
EC (1) ECSP18091593A (es)
GE (2) GEP20227382B (es)
IL (2) IL263272B2 (es)
JO (1) JOP20180121A1 (es)
MA (1) MA45234A (es)
MX (2) MX2018015757A (es)
MY (1) MY201852A (es)
NI (1) NI201800134A (es)
PE (1) PE20190416A1 (es)
PH (1) PH12018502586A1 (es)
SG (2) SG11201810763TA (es)
TN (1) TN2018000417A1 (es)
TW (2) TWI752964B (es)
UA (1) UA129793C2 (es)
WO (1) WO2017218371A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
CN109476758B (zh) 2016-06-14 2023-05-23 默沙东有限责任公司 抗-凝血因子xi抗体
KR102616666B1 (ko) 2016-12-23 2023-12-27 노파르티스 아게 인자 xi 항체 및 사용 방법
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
EP4177274A4 (en) * 2020-07-02 2024-04-03 Beijing Tuo Jie Biopharmaceutical Co. Ltd. ANTI-FXI/FXIA ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
AU2021302199A1 (en) * 2020-07-03 2023-02-23 Suzhou Alphamab Co., Ltd. Coagulation factor XI (FXI) binding protein
IL304971A (en) * 2021-02-09 2023-10-01 Arxx Therapeutics As Humanized anti-S100A4 antibody, uses and methods
US20250034277A1 (en) * 2021-11-30 2025-01-30 Suzhou Alphamab Co., Ltd. Method for preventing and/or treating thromboembolic diseases
EP4644426A1 (en) * 2022-12-30 2025-11-05 Gan & Lee Pharmaceuticals Co., Ltd. Antibody against coagulation factor xi and/or activated form factor xia thereof, and use thereof
WO2025130748A1 (zh) * 2023-12-22 2025-06-26 四川科伦博泰生物医药股份有限公司 一种抗凝血因子XI/XIa抗体制剂

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
DE68919361T2 (de) 1988-06-21 1995-05-24 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH0656382A (ja) 1992-08-04 1994-03-01 Kawasaki Steel Corp コークス乾式消火装置のバケット巻上機の吊ビーム装置
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
CN1214043C (zh) 1998-12-01 2005-08-10 蛋白质设计实验室股份有限公司 抗γ－干扰素的人化抗体
NZ521182A (en) 2000-03-03 2004-11-26 Cambridge Antibody Tech Human antibodies against eotaxin comprising VH adn VL domains and their use
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
TWI385180B (zh) 2003-07-15 2013-02-11 安美基公司 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體
CN101120087A (zh) 2004-12-21 2008-02-06 森托科尔公司 抗-il-12抗体、表位、组合物、方法和用途
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
HRP20151102T1 (xx) 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
CN103204931B (zh) 2005-12-08 2016-08-03 米德列斯公司 抗岩藻糖基-gm1的人单克隆抗体及使用抗岩藻糖基-gm1抗体的方法
PT1957539E (pt) 2005-12-08 2013-06-25 Medarex Inc Anticorpos monoclonais humanos para a proteína tirosinacinase 7 (ptk7) e sua utilização
AU2007255388B2 (en) 2006-06-06 2013-07-04 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
WO2008112004A2 (en) 2006-08-03 2008-09-18 Astrazeneca Ab ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
WO2009008916A2 (en) 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
GB0708585D0 (en) 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
CA2700723A1 (en) 2007-09-26 2009-04-02 Amgen Inc. Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
AU2016203944A1 (en) 2007-11-21 2016-07-07 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
AU2008326348B2 (en) 2007-11-21 2014-01-30 Oregon Health & Science University Anti-factor XI monoclonal antibodies and methods of use thereof
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
PL2297207T3 (pl) 2008-06-19 2019-03-29 Prothix Bv Zastosowanie przeciwciał przeciw czynnikowi XI do zapobiegania lub leczenia tworzenia skrzepliny
WO2010014854A2 (en) 2008-07-31 2010-02-04 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
CN105601742A (zh) 2008-10-31 2016-05-25 詹森生物科技公司 Toll样受体3拮抗剂
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
CA2747519C (en) 2008-12-18 2019-04-02 Oregon Health & Science University Anti-fxi antibodies and methods of use
WO2010072740A2 (en) 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
CA2755336C (en) 2009-03-20 2015-07-14 Amgen Inc. Carrier immunoglobulins and uses thereof
JP5795759B2 (ja) 2009-04-16 2015-10-14 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗ＴＮＦ−α抗体およびその用途
EP2949673A1 (en) 2009-04-27 2015-12-02 Kyowa Hakko Kirin Co., Ltd. Anti-il-3ra antibody for use in treatment of blood tumor
BR112012008665A2 (pt) 2009-10-12 2016-11-22 Pfizer tratamento de câncer
US20120316071A1 (en) 2009-11-04 2012-12-13 Vaughn Smider Methods for affinity maturation-based antibody optimization
EP2516624B1 (en) 2009-12-23 2020-02-05 Merck Sharp & Dohme Corp. Cell line 3m
AU2011212997A1 (en) * 2010-02-03 2012-08-16 Trilogy Ip Holdings, Inc. Mobile communication plan offerings
DK3336225T3 (da) 2010-07-16 2020-03-30 Adimab Llc Antistofbiblioteker
AU2011286407A1 (en) 2010-08-06 2013-02-21 Amgen Use of HER3 binding agents in prostate treatment
TWI589587B (zh) 2010-11-19 2017-07-01 衛材Ｒ＆Ｄ企管股份有限公司 中和性抗－ｃｃｌ２０抗體
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
CN103619882B (zh) 2011-04-01 2016-10-19 纪念斯隆-凯特琳癌症中心 对hla-a2呈递的wt1肽特异的t细胞受体样抗体
ES2929575T3 (es) 2011-06-06 2022-11-30 Novo Nordisk As Anticuerpos terapéuticos
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
DK2650310T3 (en) 2012-04-13 2016-09-12 Rottapharm Biotech Srl The anti-ADAMTS-5 antibody, derivatives and uses thereof
BR112014027952B1 (pt) 2012-05-10 2022-06-21 Bayer Pharma Aktiengesellschaft Anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi, seu uso, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor
JP6441792B2 (ja) 2012-05-17 2018-12-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｇｆｒに結合する抗原結合蛋白質
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
AU2014331118B2 (en) 2013-10-01 2019-07-25 Medimmune Limited Methods of treating and diagnosing alpha-V-beta-6 overexpressing cancer
MX2016011885A (es) 2014-03-20 2016-12-02 Japan As Represented By Director-General Of Nat Inst Of Infectious Diseases Anticuerpo con actividad inhibidora de inyeccion frente al virus de hepatitis c.
MY191346A (en) 2014-06-03 2022-06-17 Xbiotech Inc Compositions and methods for treating and preventing staphylococcus aureus infections
CA3090240A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
LT3280441T (lt) 2015-04-07 2021-11-25 Alector Llc Anti-sortilino antikūnai ir jų naudojimo būdai
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
CN108884169B (zh) 2016-01-22 2022-03-22 默沙东公司 抗凝血因子xi抗体
CN109476758B (zh) * 2016-06-14 2023-05-23 默沙东有限责任公司 抗-凝血因子xi抗体
PE20191319A1 (es) 2016-09-20 2019-09-24 Bayer Pharma AG Anticuerpos novedosos contra el factor xi y sus usos

Also Published As

Publication number Publication date
TWI752964B (zh) 2022-01-21
MA45234A (fr) 2019-04-17
JP2021101720A (ja) 2021-07-15
CL2018003565A1 (es) 2019-03-22
AU2020210233B2 (en) 2024-03-07
US20200270364A1 (en) 2020-08-27
US10676536B2 (en) 2020-06-09
US20230287141A1 (en) 2023-09-14
NZ786448A (en) 2025-06-27
JP2019521978A (ja) 2019-08-08
US11479615B2 (en) 2022-10-25
MX2018015757A (es) 2019-05-30
KR102379580B1 (ko) 2022-03-29
US12275800B2 (en) 2025-04-15
IL263272B2 (en) 2025-07-01
CL2024000367A1 (es) 2024-08-23
CA3172367A1 (en) 2017-12-21
GEP20227382B (en) 2022-05-25
US11485794B2 (en) 2022-11-01
KR20190018504A (ko) 2019-02-22
NI201800134A (es) 2019-03-05
ECSP18091593A (es) 2019-01-31
AR108717A1 (es) 2018-09-19
NZ786442A (en) 2025-06-27
CN109476758A (zh) 2019-03-15
US20200317811A1 (en) 2020-10-08
EA201892716A1 (ru) 2019-05-31
NZ748743A (en) 2025-06-27
JP7277500B2 (ja) 2023-05-19
CA3025869A1 (en) 2017-12-21
AU2017286432B2 (en) 2020-09-24
GEAP202114983A (en) 2021-12-10
IL263272A (en) 2018-12-31
JOP20180121A1 (ar) 2018-12-12
CA3025869C (en) 2025-10-07
TW202214702A (zh) 2022-04-16
BR112018075858A2 (pt) 2019-04-02
NZ786447A (en) 2025-06-27
EP3469002A1 (en) 2019-04-17
AU2017286432A1 (en) 2018-12-06
US11661460B2 (en) 2023-05-30
AU2020210233A1 (en) 2020-08-20
TW201802120A (zh) 2018-01-16
IL315266A (en) 2024-10-01
US20200255542A1 (en) 2020-08-13
CR20180583A (es) 2019-07-02
KR102218714B1 (ko) 2021-02-24
US20200308302A1 (en) 2020-10-01
CO2018013434A2 (es) 2018-12-28
PH12018502586A1 (en) 2019-10-07
SG11201810763TA (en) 2018-12-28
TN2018000417A1 (en) 2020-06-15
MX2023012740A (es) 2024-02-23
US20170355780A1 (en) 2017-12-14
DOP2018000284A (es) 2019-01-31
IL263272B1 (en) 2025-03-01
JP7022081B2 (ja) 2022-02-17
UA129793C2 (uk) 2025-08-06
NZ786443A (en) 2025-06-27
SG10202103120UA (en) 2021-05-28
NZ786444A (en) 2025-06-27
TWI802193B (zh) 2023-05-11
MY201852A (en) 2024-03-20
WO2017218371A1 (en) 2017-12-21
CN116425879A (zh) 2023-07-14
US11512142B2 (en) 2022-11-29
AU2024201084A1 (en) 2024-03-14
CN109476758B (zh) 2023-05-23
KR20210021124A (ko) 2021-02-24

Similar Documents

Publication Publication Date Title
PE20190416A1 (es) Anticuerpos antifactor de la coagulacion xi
CY1124691T1 (el) Διειδικα αντισωματα ειδικα για pd1 και τιμ3
CY1125440T1 (el) Αντι-τιμ-3 αντισωματα και συνθεσεις
CY1125327T1 (el) Anti-pd-1 αντισωματα και συνθεσεις
CY1124182T1 (el) Αντισωματα anti-tmprss2 και θραυσματα δεσμευσης αντιγονου
CR20190435A (es) Anticuerpos biespecíficos de unión específica a pd1 y lag3
CL2019002196A1 (es) Anticuerpos humanos neutralizantes que se unen a hemaglutinina de influenza a. (divisional solicitud 201701610)
CO2019013381A2 (es) Anticuerpo anti–receptor de igf-i
CL2019000658A1 (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo.
CR20170026A (es) Anticuerpos anti-tau humanizados
ECSP19044484A (es) Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x
CU24568B1 (es) Anticuerpo inhibidor de masp-3
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
CO2017013356A2 (es) Anticuerpos de factor xi
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
JOP20170004B1 (ar) الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
MX388181B (es) Anticuerpos anti-pd-1.
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
MA43660A (fr) Anticorps anti-facteur xi de coagulation
CL2019000659A1 (es) Anticuerpo que se une específicamente a il-17a y fragmento funcional del mismo.
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
CO2017010316A2 (es) Anticuerpo monoclonal aislado y / o recombinante y un método para identificar la infección por el virus de chikungunya glycoprotein e2 mediante el contacto con una muestra con un anticuerpo o fragmento de anticuerpos con secuencias cdr de cadena pesada y ligera
DK3543337T3 (da) Hidtil ukendt fab-fragment af et anti-humant muc1-antistof
MX390723B (es) Metodo para medir la reactividad del factor de coagulacion viii (fviii).